USA: Engineering Praxair Begins Work to Construct Fifth Liquid Hydrogen Plant

Editor: Ahlam Rais

On completion, the new facility is expected to produce 30 tonnes of high purity liquid hydrogen per day. The plant is being established owing to the increase in demand from multiple sectors.

Related Vendors

Praxair’s new plant, scheduled to start up in 2021, will produce over 30 tonnes per day of high purity liquid hydrogen.
Praxair’s new plant, scheduled to start up in 2021, will produce over 30 tonnes per day of high purity liquid hydrogen.
(Source: Deposit Photos)

Connecticut/USA – Praxair, a wholly-owned subsidiary of Linde, the leading global producer of liquid hydrogen, has recently announced that it has commenced construction of its fifth liquid hydrogen plant in the U.S., adding geographic and source diversification. The new investment in La Porte, Texas, is in response to growing demand from customers in sectors such as material handling, aerospace, manufacturing, metals, energy and electronics.

Praxair’s new plant, scheduled to start up in 2021, will produce over 30 tonnes per day of high purity liquid hydrogen. It will be integrated with the recently constructed air separation plant in La Porte, resulting in energy and capital cost savings. The new plant will complement Praxair’s existing liquid hydrogen plants in California, Alabama, Indiana and New York and will enhance supply reliability.

Major Plant Engineering GROAB is a project database for international major plant engineering and construction. You can find more than 5500 projects within 13 categories. Learn more about GROAB and test the database.

Praxair operates over 50 hydrogen generation plants and six pipeline networks globally. The La Porte hydrogen liquefier will be integrated with Praxair’s 350-mile gulf coast hydrogen pipeline network and storage cavern.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:45590919)